Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Boots explains, as it tries to get your cells to pick up and use the excess sugar
Semaglutide Quick Facts: Drug Class: GLP-1 receptor agonist Brand Names: Ozempic (diabetes), Wegovy (weight loss), Rybelsus (oral) FDA Approval: Ozempic approved 2017, Wegovy approved 2021 Manufacturer: Novo Nordisk Dosing: Once weekly injection, starting at 0.25 mg, maximum 2.4 mg Clinical Trial Name: STEP trials (Semaglutide Treatment Effect in People with obesity) Average Weight Loss: 10-15% of body weight over 68 weeks Tirzepatide Quick Facts: Drug Class: Dual GIP/GLP-1 receptor agonist Brand Names: Mounjaro (diabetes), Zepbound (weight loss) FDA Approval: Mounjaro approved 2022, Zepbound approved 2023 Manufacturer: Eli Lilly Dosing: Once weekly injection, starting at 2.5 mg, maximum 15 mg Clinical Trial Name: SURMOUNT trials (Study to evaluate tirzepatide in obesity or overweight) Average Weight Loss: 15-22% of body weight over 72 weeks Primary Difference: The main distinction is that semaglutide activates only GLP-1 receptors, while tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors
Weight loss curve showed no plateau at study end, suggesting potential for continued improvement with longer treatment
Xing X, Jiang H, Zhou Q, Xing H, Jiang H, Wang S
US$ 28.85
US$ 29.91
US$ 22.70
US$ 27.05
US$ 21.49
US$ 23.71
US$ 28.85
